Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects*
- 16 October 1998
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 64 (4) , 412-423
- https://doi.org/10.1016/s0009-9236(98)90072-8
Abstract
To understand the pharmacokinetic and pharmacodynamic properties of recombinant human erythropoietin (epoetin alfa) and to continue to optimize dosing regimens by determining whether administration of single high doses of epoetin alfa is as effective as repeated administration. Epoetin alfa was administered as single subcutaneous doses of 300, 450, 600, 900, 1200, 1350, 1800, and 2400 IU/kg and in multiple subcutaneous dose regimens: 150 IU/kg 3 times a week for 4 weeks and 600 IU/kg once per week for 4 weeks in 2 open-label, randomized placebo-controlled studies in healthy volunteers. The absorption rate of epoetin alfa after subcutaneous administration was independent of dose, whereas clearance was dose-dependent in that it decreased with increasing dose. There was a linear relationship between response measured as percentage of reticulocytes area under the curve (AUC) and erythropoietin AUC for single doses up to 1800 IU/kg. Beyond the 1800 IU/kg dose, there was a saturation of response. The mean percentage of reticulocytes after single-dose regimens began to increase by days 3 to 4, reached their maximum at days 8 to 11, and returned to baseline values by day 22. In contrast, the mean percentage of reticulocytes after both multiple-dose regimens were maintained above baseline values through day 22 as both regimens stimulated modest but sustained increases in percentage of reticulocytes (1% to 2%). The mean percentage of reticulocytes AUC for 600 IU/kg epoetin alfa given once a week for 4 weeks was apparently greater than the mean percentage of reticulocytes AUC for 150 IU/kg 3 times a week for 4 weeks. Although daily oral iron supplementation was given, mean serum ferritin levels declined by approximately 75% through day 22 in subjects treated with multiple doses of epoetin alfa. These findings show that the pharmacologic response to epoetin alfa is a function of dose and dosing regimen. Repeated administration of epoetin alfa was more effective in stimulating a reticulocyte response than single-dose administration of the same total amount of epoetin alfa.Keywords
This publication has 16 references indexed in Scilit:
- Erythropoietin-the first 90 yearsClinical and Laboratory Haematology, 1996
- Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptorCell, 1995
- Kinetic Evaluation of Nonlinear Drug Elimination by a Disposition Decomposition Analysis. Application to the Analysis of the Nonlinear Elimination Kinetics of Erythropoietin in Adult HumansJournal of Pharmaceutical Sciences, 1995
- Epoetin AlfaDrugs, 1995
- Clinical Pharmacokinetics of Epoetin (Recombinant Human Erythropoietin)Clinical Pharmacokinetics, 1991
- The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.British Journal of Clinical Pharmacology, 1990
- Cloning and expression of the human erythropoietin gene.Proceedings of the National Academy of Sciences, 1985
- Isolation and characterization of genomic and cDNA clones of human erythropoietinNature, 1985
- Effect of pure erythropoietin on DNA‐synthesis by human marrow day 15 erythroid burst forming units in short‐term liquid cultureBritish Journal of Haematology, 1984
- Serum ferritin assay and iron status in chronic renal failure and haemodialysis.BMJ, 1975